BioCentury | Nov 13, 2020
Product Development

A huge sigh of relief, but a long road ahead: AZ’s Pangalos on COVID-19 in a BioCentury audio interview

The interim data from Pfizer and BioNTech showing 90% efficacy this week was at the same time a big step and a baby step for the field, according to Mene Pangalos, who sees a long...
BioCentury | Oct 2, 2020

Election volatility may drive investors toward low-risk opportunities in 4Q

The increasing likelihood of a contested U.S. presidential election means the markets could be in for a high dose of volatility in 4Q20, pushing the pause button on a record year for IPOs and sending...
BioCentury | Oct 1, 2020
Product Development

‘Flipting’ the switch: a technological prescription for lower drug costs

It is time to do away with the middlemen that drive up drug costs for patients through their complex system of kickbacks. This week’s House committee hearings on drug pricing are a sign the...
BioCentury | Sep 19, 2020
Politics, Policy & Law

What it will take to get to mass asymptomatic screening for COVID-19

Making widespread COVID-19 screening a priority for public health will require a broad and abundant basket of testing technologies, and a coordinated plan for how to use and pay for them. The first barrier...
BioCentury | Sep 9, 2020
Product Development

McMurry-Heath: COVID-19 raises stakes for industry to take the lead on promoting science: a BioCentury audio interview

Michelle McMurry-Heath, three months into her role as president and CEO of BIO, sees the pandemic as a crucial time for the biopharma industry to tell its story better to the public, and ensure its...
BioCentury | Aug 27, 2020
Politics, Policy & Law

CDC reversal on asymptomatic COVID-19 testing, guided by White House task force, prompts backlash

CDC’s flip on asymptomatic COVID-19 testing in exposed individuals has drawn rebuke from at least two state governors, and further jeopardizes public confidence in the agency’s independence. According...
BioCentury | Jul 31, 2020

Polyphor gains financial cushion ahead of Phase III readout of lone clinical program

A new equity financing should give Polyphor a little more financial breathing room as the Swiss biotech tries to broaden its pipeline and move away from an all-or-nothing Phase III coin flip in 1Q21. Polyphor...
BioCentury | May 27, 2020
Top Story

Arcus keeps its independence in deal that gives Gilead access to targets ripe for combinations

Gilead’s partnership with Arcus gives it access to a pipeline ripe for immuno-oncology combinations around closely watched targets, such as TIGIT. But the agreement doesn’t mirror Gilead’s last deal, in which partnering negotiations with Forty...
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

Flagship’s Repertoire aims to identify which TCRs and antigens matter in disease and apply those insights to biomarkers and therapies, starting with a cytokine-loaded T cell candidate for cancer. Repertoire Immune Medicines Inc. emerged in...
BioCentury | May 14, 2020
Product Development

Collaborating against the challenges of COVID, a conversation with Novartis’ R&D heads

In the latest BioCentury This Week -- Special Report podcasts , Novartis R&D heads John Tsai and Jay Bradner discuss with BioCentury the challenges facing drug developers as they attempt to develop countermeasures against COVID-19, and...
Items per page:
1 - 10 of 223